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SUMMARY 
This report describes the results of a multicentre collaborative study comparing the safety and efficacy 
of alprazolam with imipramine in patients suffering from major depressive disorder. Two hundred and 
eight patients diagnosed as major depression as per DSM-III criteria were randomly allocated to alprazo-
lam (N= 105) or imipramine (N = 103) in a double-blind fashion. Detailed assessments were carried out 
for a period of six weeks. Results revealed that alprazolam was as effective as imipramine as an antide-
pressant. Side effectswere less frequently reported with alprazolam. 
Alprazolam is a new benzodiazepine 
compound that differs from classic benza-
diazepines by the incorporation of a 
triazole ring in its basic structure. It 
has a different metabolic pathway with 
rapid absorption and elimination. The 
addition of the triazole ring to the basic 
structure is believed to have given anti-
depressant properties to alprazolam 
(Feighner, 1982). Compared to conven-
tional antidepressants, alprazolam is 
reported to be less toxic (Fawcett and 
Kravitz, 1982). It is also free of anticho-
linergic side effects. 
Several controlled trials have evalua-
ted the efficacy of alprazolam in the 
treatment of major depression (Rickelset 
al., 1985; Rickelset al., 1987; Feighner 
et al., 1983 a and b). These studies have 
shown that alprazolam is as effective as 
conventional antidepressants like imipra-
mine. Further the incidence of adverse 
effects have been noted to be lesser with 
alprazolam. 
The present investigation is a double 
blind study carried out in four centres at 
Bangalore, Bombay, Madras and Delhi to 
assess the safety and efficacy of alprazolam 
in comparison with imipramine in pati-
ents with major depressive disorder. 
Methodology 
a. Pre-trial meeting of the researh staff: 
The investigators and research staff of the 
four participating centres had a pre-trial 
meeting to discuss the study protocol. 
Each of the study instrument was discu-
ssed in detail. Inter-rater reliability 
exercise were carried out using audio-
taped interviews as well as live interviews. 
Research staff who joined the project 
afresh were provided similar exposure. 
b. Selection criteria : Patients consi-
dered for participation were males and 
non pregnant females-using contraception 
or not-of childbearing potential. Only 
outpatients suffering from moderate to 
severe depression were included. Patients 
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were required to meet the Feiglmer's crite-
ria for primary depression (Feighner et al., 
1972) as well as the criteria for major 
depression as per the Diagnostic and 
Statistical Manual (DSM-III) of the 
American Psychiatric Association (1980). 
In addition, they were required to have a 
minimum baseline score of 18 on the 21-
Hamiltoii Depression Rating Scale 
(HDRS) (Hamilton, 1960), a minimum 
score of 8 on the Raskin depression scale 
(Raskin et al., 1970) and a Govi anxiety 
rating scale (Lipman and Govi, 1976) score 
less than or equal to Raskin depression 
scale score. Patients with other psychia-
tric illness, alcohol or substance abuse, 
and concurrent use of other psychotropic 
medication were excluded. Similarly, 
patients with bipolar affective disorder 
ami those with marked psychomotor 
retardation were excluded from the study. 
VVritten informed consent was obtai-
ned from all the patients. Informed 
c ms-nt information was prepared in 
English and the local languages based on 
international guidelines (CIOMS and 
WHO, 1932), and this information was 
read out to all the potential participants. 
Doubts if any were clarified. 
c. Study procedure : A three to seven 
day placebo washout period preceded the 
study prop r. Patients who showed signi-
ficant improvement during the washout 
period were eliminated from the study. 
The pre-trial screening involved collection 
of demographic, medical and psychiatric 
history; detailed physical examination 
and recording of vital signs; and bioche-
mical investigations which included 
complete blood counts, urinalysis, estima-
tions of serum creatinin. serum alkaline 
phosphatase, serum glutamic oxaloacetic 
transminase and serum bilirubin levels. 
All .iss.-ssments were reeor led in standard 
format data sheets. 
Patients Wi re allocated to alprazolam 
or imipramincin a double blind random 
fashion. The randomization was such 
that in each consecutive group of six 
patients, 3 were on alprazolam and 3 
were on imipramine. The drugs were 
dispensed in identical capsules, each cap-
sule containing alprazolam 0.5 mg or 
imipramine 2" mg. Patients were started 
with one capsule twice daily. Within 
three days, the dosage was adjusted to one 
capsule thrice daily. Dosage was further 
increased at weekly intervals, subject to a 
maximum of 3 capsules thrice daily. If 
significant side effects appeared, the 
dosage was reduced and if they persisted 
at the minimum dose, or when the clini-
cal condition worsened, patient was 
withdrawn from the study. The drug 
code of each patient was kept in a sealed 
envelope which could be opened in case 
of an emergency. Once the drug code 
was broken, the data would be elimi-
nated from further analysis-
Patients were requested to follow 
their regular eating habits They were 
advised not to use alcohol or other psycho-
tropic drugs. Follow up evaluation 
were done at the end of the first, second, 
fourth and sixth week of treatment using 
the following scales : Hamilton Depre-
ssion Rating Scale (HDRS), Hamilton 
Anxiety Rating Scale (HARS) (Hamilton, 
1959), Physician's Global Impression, and 
Patient's Global Impression. Treatment 
emergent symptoms were recorded at each 
evaluation and detailed physical examina-
tion and laboratory assays were repeated 
at the final evaluation. Treatment safety 
was assessed based on the number and 
severity of adverse reactions reported, 
physical examination and laboratory 
investigations. Statistical analysis of the 
data were performed using parametric 
and non parametric tests. 
Results 
A total of 208 patients were enrolled 
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There were 56 males and 49 females in 
the alprazolam group and 62 males and 
41 females in the imipramine group. The 
mean age of the alprazolam group was 
35.0± 10.9 years, and that of the imipra-
mine group was 32-3±9 3 years. There 
were no differences between the two 
groups with respect to age, sex, marital 
status, occupational adjustment, family 
life adjustment or precipitating stress 
factors. 
Sixty percent of the alprazolam group 
and 62% of the imipramine group had an 
illness of more than one year duration, 
Thirty three percent of the alprazolam 
group and 35 % of the imipramine group 
reported previous treatment for emotional 
problems. 
Table 1 shows the dropout rates in 
the alprazolam and imipramine groups. 
The drop-out rate was significantly higher 
for the imipramine group during the first 
and second weeks- Overall 25% of the 
alprazolam group and 33% of the imipra-
mine group dropped out of the trial. 
TABLE 1—Number of patients completing the 
different periods of assessment. 
{Percentage in parentheses) 
Period of 
Assessment. 
Alprazolam  Imipramine 
Initial 
Weelc-I 
Week II 
Week IV 
Week-VI 
105 (100.0) 
98 ( 93.3) 
91 ( 86.7) 
81 (77.1) 
76 ( 75.2) 
103 (100.0) 
86 ( 83.5)* 
76 ( 73.8)* 
69 ( 67.0) 
69 ( 67.0) 
*The rate of drop out was higher in the imipramine 
group in the first week (p<0.05) and second 
week (p<0.02). 
Table 2 and table 3 show the mean 
scores with standard deviation on the 
HRDS and HARS for the two groups. 
The two drugs were equally effective at 
all the periods of assessment. The drop 
in the mean HDRS scores was 59% for 
the alprazolam group and 61 % for the 
imipramine group. On the Physician's 
Global Impression scale, 80% of the 
alprazolam and 83% of the imipramine 
group were rated as very much or much 
improved. Three patients in the alpra-
zolam group and two patients in the 
imipramine group were rated as having 
showed no change or minimally worse at 
the end of six weeks of therapy. On the 
patient's Global Impression Scale 77% of 
the alprazolam roup and 83% of the 
imipramine felt that they were very much 
or much better. Seventy eight percent 
of patients in both the groups evaluated 
the efficacy of the drugs as moderate to 
marked. 
TABLE 2— Mean±S. D. scores of the alprazo-
lam group and imipramine group on 
the Hamilton Despression Rating 
Scale. 
Period of 
assessment. 
Alprazolam 
Mean ± S. D. 
Imipramine 
Mean ± S. D. 
Initial 
Week-I 
Week-II 
Week-IV 
Week-VI 
23.81 ± 14.95 
16.65 ± 10.62 
14.40 ± B.17 
12.93 ± 7.17 
9.75 ± 4.63 
23.44 ± 14.56 
17.88 ± 11.18 
14.11 ± 8.49 
11.26 ± 6.46 
9.20 ± 4.72 
*The comparison of mean scores of the two groups 
at various period of assessment is statistically in 
significant (by't' test). 
The mean number of capsules per 
day (alprazolam 0.5 mg; imipramine 25 
mg) in the first week was 3.2±0.8 of 
alprazolam and 3.4±0.9 of imipramine. 
This was5.0±1.6 and 5.1 ±1.6 respecti-
vely at the end of six weeks. Eighty six 
percent of subjects, in either group requi-
red less than six capsules per day. 
The frequency of side effects were 
higher with imipramine compared to 
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of patients on imipramine reported insom-
nia (p<0.01) and tremor (p<0.01) as 
side effects. None of the side effects 
reported was significantly more in the 
alprazolam group. No significant 
changes in physical examination or labo-
ratory data Were observed in either of the 
groups. 
Discussion 
Depressive disorders constitute a sig-
nificant proportion of mental health 
problems. A systematic epidemiological 
survey in Vellore town found the preva-
lence of depressive neurosis to be 33 per 
thousand population (Verghese and Beig, 
1974). Pharmacotherapy forms an impor-
tant component of the overall manage-
ment of depression. Till recently two 
major groups of antidepressants were 
available, namely the tricyclic antidepre-
ssants and monoamine oxidase inhibitors. 
The frequent occurence of undesirable 
side effects is a disadvantage in the use 
of these drugs. Hence a drug like 
alprazolam with its reported antidepre 
ssant effect and lesser side effect profile 
would appear to be an advantage in the 
management of depression. The present 
study assumes importance in this context. 
Although a number of factors might 
have contributed to the drop-out from 
the trial, the higher rate of drop-out in 
the imipramine group as well as the 
higher frequency of re ported side effects 
in this group suggest that side effects of 
this drug might have contributed to non 
compliance. 
The results of the present study show 
that alprazolam is as effective as imipra-
mine in major depressive disorder. This 
finding >s consistent with earlier reports 
which have used similar methodology 
(Rickclset al , 1985; Rickeks et a!., 1987; 
Feighncr et al., 1983: a and b). Like 
the eirlier studies, the present study 
found lesser incidence of undesirable 
adverse effects with alprazolam. This 
would especially favour the use of alpra-
zolam in patients with cardiac disease 
and in elderly patients where tricyclic 
antidepressants are contraindicated. 
Further, since alprazolam shows a higher 
margin of safety compared to the other 
benzodiazepines, potential for fatal toxic 
reactions are less likely compared to 
tricyclic antidepressants. 
Recently there have been reports of 
certain adverse effects of alprazolam like 
dependence (Juergens and Morse, 1986), 
emergence of depressive symptoms during 
the treatment of panic disorder (Lydiard 
et al., 1987) and exacerbation of symptoms 
of panic following discontinuation of 
alprazolam (Fyeret al., 1987). Since the 
present study was limited to an evaluation 
period of six weeks, more long term 
studies arc required to understand the 
safety and efficacy of alprazolam. 
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